Provided by Tiger Fintech (Singapore) Pte. Ltd.

Becton Dickinson

228.19
+0.69000.30%
Volume:884.29K
Turnover:200.83M
Market Cap:65.52B
PE:38.41
High:228.59
Open:226.93
Low:225.12
Close:227.50
Loading ...

Company Profile

Company Name:
Becton Dickinson
Exchange:
NYSE
Establishment Date:
1897
Employees:
74000
Office Location:
1 Becton Drive,Franklin Lakes,New Jersey,United States
Zip Code:
07417-1880
Fax:
- -
Introduction:
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Directors

Name
Position
Thomas E. Polen
Chairman, Chief Executive Officer and President
Bertram L. Scott
Independent director
Carrie L. Byington
Independent director
Catherine M. Burzik
Independent director
Christopher Jones
Independent director
Claire M. Fraser Liggett
Independent director
Gregory J. Hayes
Independent director
Jeffrey W. Henderson
Independent director
Joanne Waldstreicher
Independent director
R. Andrew Eckert
Independent director
Timothy M. Ring
Independent director
William M. Brown
Independent director

Shareholders

Name
Position
Thomas E. Polen
Chairman, Chief Executive Officer and President
Christopher J. DelOrefice
Executive Vice President and Chief Financial Officer
Pamela L. Spikner
Senior Vice President, Chief Accounting Officer and Controller
Antoine Ezell
Executive Vice President,President,and Chief Marketing Officer
David Shan
Executive Vice President and Chief Integrated Supply Chain Officer
Michael Feld
Executive Vice President and President, Life Sciences
Michael Garrison
Executive Vice President and President, Medical Segment
Michelle Quinn
Executive Vice President and General Counsel
Pavan Mocherla
Executive Vice President and President, Greater Asia
Richard Byrd
Executive Vice President and President, Interventional Segment
Roland Goette
Executive Vice President and President, EMEA
Shana Neal
Executive Vice President and Chief People Officer